It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4 + Foxp3 − T cells into CD4 + Foxp3 + regulatory T cells (iTregs) in transplantation setting. It is not clear whether RPM can similarly generate suppressor CD8 + T cells to facilitate graft acceptance. In this study, we investigated the ability of short-term RPM treatment in promoting long-term acceptance (LTA) of MHC-mismatched skin allografts by generating a CD8 + suppressor T-cell population. We found that CD4 knockout (KO) mice (in C57BL/6 background, H-2 b ) can promptly reject DBA/2 (H-2 d ) skin allografts with mean survival time (MST) being 13 days (p < 0.01). However, a short course RPM treatment in these animals induced LTA with graft MST longer than 100 days. Adoptive transfer of CD8 + T cells from LTA group into recombination-activating gene 1 (Rag-1)-deficient mice provided donor-specific protection of DBA/2 skin grafts against cotransferred conventional CD8 + T cells. Functionally active immunoregulatory CD8 + T cells also resided in donor skin allografts. Eighteen percent of CD8 + suppressor T cells expressed CD28 as measured by flow cytometry, and produced reduced levels of IFN-γ, IL-2, and IL-10 in comparison to CD8 + effector T cells as measured by ELISA. It is unlikely that CD8 + suppressor T cells mediated graft protection via IL-10, as IL-10/Fc fusion protein impaired RPM-induced LTA in CD4 KO mice. Our data supported the notion that RPM-induced suppressor CD8 + T cells home to the allograft and exert donor-specific graft protection.
INTRODUCTION
investigation of suppressor T cells under each unique condition is necessary before considering T-cell manipulation or enrichment therapies (23, 37, 41, 42) . Recent evi-Induction of immunological tolerance to transplanted grafts remains an elusive goal. Recent advances in char-dence suggests that certain CD8 + T lymphocytes can act as regulatory cells in suppressing immune responses acterizing CD4 + Foxp3 + regulatory T cells (Treg), a subset of CD4 + T cells known to be essential for creation (15) . These CD8 + Treg cells can suppress autoimmune experimental encephalomyelitis and play a role in oral and maintenance of self-tolerance (34, 36, 38, 43) , have led to a renaissance of this field, and efforts have been tolerance (21, 24, 30) . Nevertheless, the precise identity of these cells and the molecular basis for their immu-focused on reinvigorating the traditional immunosuppressive agents with novel applications in promoting nosuppressive properties has not been fully characterized, particularly in transplant models. Several cell Tregs. Rapamycin (RPM) has been shown to enable the expansion of natural Tregs and induce the de novo gen-surface markers are reported to be associated with CD8 + immunoregulatory T cells, including CD25, eration of Tregs in murine models (2, 44, 45) . More recently, RPM has been reported to elevate Treg propor-CD122, Qa-1, and lack of CD28 (3,12,19,28). Herein, we describe the effect of RPM on the development of tions in renal transplant recipients (18) . It is not clear whether RPM can similarly generate suppressor CD8 + T CD8 + T-cell-driven immunoregulation in a fully major histocompatibility complex (MHC)-mismatched skin cells to facilitate acceptance.
It is generally taken that there exist multiple types of transplant model using CD4 knockout (KO, H-2 b ) recipients, in the absence of the dominant CD4 + Foxp3 + regulatory T cells that may exert suppressive functions under specific conditions (22, 37, 48) . Therefore, thorough Treg population.
MATERIALS AND METHODS
form of IL-10 (49), was administered as a monotherapy or in combination with RPM at 5 µg (IP) every other Animals day for 5 days in the designated study groups (49). Graft Male C57BL/6 CD4KO (H-2 b ) (CD4 tm1Mak ; CD4 antisurvival was assessed by daily visual inspection. Rejecgen; targeted mutation 1, Tak Mak), C57BL/6 CD8KO tion was defined as the complete necrosis and loss of (H-2 b ) (CD8atm1Mak; CD8 antigen, alpha chain; tarviable skin tissue. geted mutation 1, Tak Mak), DBA/2 (H-2 d ), C3H/He (H-2 k ), and C57BL/6J-Rag KO (H-2 b ) (Rag1 tm1Mom , Preparation of Purified CD8 + T Cells recombination activating gene 1; targeted mutation 1, CD8 + T cells were purified as previously described Peter Mombaerts) mice were purchased from the Jack- (29) . After red blood cells (RBCs) were lysed by hyposon Laboratory (Bar Harbor, ME). Animal use and care tonic shock, lymph node and spleen cells were depleted was in compliance with guidelines established by the of macrophages, granulocytes, B cells, and erythrocytes animal care committee at Beth Israel Deaconess Medical by incubating them first with anti-CD11b (Mac-1) mAb, Center (Boston, MA).
anti-GR1 (8C5) mAb, anti-CD4 (GK1.5) mAb, anti-CD45R/B220, and anti-erythrocytes mAbs and then Reagents treated with magnetic beads coupled to anti-rat Ig. Puri-The following anti-mouse monoclonal antibodies fied CD8 + T cells were negatively selected using MACS (mAbs) were purchased from BD Pharmingen (San columns. The purity of the resultant CD8 + T-cell popula-Diego, CA) and used for cell surface and intracellular tions as determined by flow cytometry was greater than staining: fluorescein isothiocyanate (FITC)-labeled anti-95% in all experiments. CD8 + T cells purified from the mouse CD4 (clone RM4-5), anti-mouse CD8 (53-6.7) naive CD4 KO mice were used and defined as effectors, and isotype control Abs; phycoerythrin (PE)-labeled while the CD8 + T cells purified from the long-term acanti-CD25 (3C7), anti-CD122 (TM-β1), anti-CD28 ceptance (LTA) RPM-treated CD4 KO recipients were (37.51), anti-CD44 (IM7), anti-IL-10 (interleukin-10; used and defined as Tregs. JES5-16E3), anti-IFN-γ (interferon-γ; XMG1.2), anti-Foxp3 (forkhead box P3; MF23), anti-CD11b (M1/70), Adoptive Cell Transfer anti-GR1 (granulocyte differentiation antigen; RB6 CD8 + T cells were obtained from CD4 KO naive 8C5), anti-CD4 (GK1.5), anti-CD45R/B220 (RA3 6B2), mice or LTA RPM-treated hosts >100 days post-skin anti-erythrocytes (TER-119), anti-Fcγ-RII/III (2.4G2), grafting, and were adoptively transferred in various mixpurified rat anti-mouse CD4 (H129.19), anti-CD8a (53tures into Rag−/− hosts via tail vein injection. Mice were 6.7), anti-CD3 (145-2C11), and anti-CD28 (37.51); and transplanted 24 h later with skin allografts. CyChrome anti-mouse CD8 (53-6.7 Blood samples were drawn from the tail of control (Franklin Lakes, NJ), and nylon cell strainer (BD, Bed-Rag−/− mice, or from the Rag−/− recipient mice 30 days ford, MA). RPM (Wyeth-Ayerst, Princeton, NJ) was after retransplantation of RPM-treated LTA skin or fresh prepared in carboxymethyl cellulose for IP injections.
DBA/2 grafts. RBCs were lysed by hypotonic shock. IL-10/Fc was produced and purified as previously re-Immunostaining of these cells was performed on ice for ported (49).
30 min per step. To prevent nonspecific binding of mAb, all samples were preincubated with blocking anti-Fcγ-Skin Transplant and Immunosuppression Protocol RII/III mAb (2.4G2). The following Abs combinations were used for surface phenotype analysis: CyChrome Full-thickness tail skin grafts (1 cm 2 ) from donor mice were transplanted onto the thoracic wall of recipi-anti-CD8, FITC anti-CD4, PE anti-CD25/anti-CD28/ anti-CD122/anti-CD44. For intracellular staining of Foxp3, ent mice. The skin grafts were secured with an adhesive bandage for 7 days posttransplantation. One group of cells were first surface stained with FITC anti-CD8, fixed, permeabilized, and then stained with PE-anti-recipient mice was treated with RPM at 3 mg/kg/day IP on days 0, 1, and 2 followed by treatment every other Foxp3, anti-IFN-γ (XMG1.2), or anti-IL-10 (JES5?16E3). All samples were analyzed using a FACSort equipped day for 2 weeks, as previously reported (26) , while the second group was not treated. IL-10/Fc, a long-lived with CellQuest software (BD Biosciences, Mountain View, CA). Data were collected and analyzed by gating (donor-specific or donor-nonspecific stimulator cells mixed with tolerant CD8 + T cells vs. donor-specific stimulator on CD8 + populations. cells mixed with naive control CD8 + T cells) in the main In Vitro Proliferation and Cytokine Production two groups (1 × 10 5 and 2 × 10 5 cells) was performed using the two-way ANOVA method, followed by Bonf-CD8 + T cells were purified from lymph nodes and spleen of naive CD4 KO mice or from LTA RPM-erroni posttest. To compare FACS analysis data from CD8 + T cells isolated from naive versus LTA mice, we treated hosts. CD8 + T cells were then cultured in 96-well U-bottom plates coated with anti-CD3 (1.0 mg/ml) and
used unpaired t-test. And for ELISA cytokine assay, we used chi-square test to compare naive versus tolerant anti-CD28 mAbs (0.5 mg/ml) and culture supernatants at day 3, 5, and 7 were collected. IL-2, IL-4, IL-5, IL-groups (day 5 and day 7). A value of p < 0.05 was considered statistically significant. 6, IL-10, tumor necrosis factor-α (TNF-α) and IFN-γ production was measured by ELISA assays. Data are RESULTS representative of three separate experiments.
Short-Term Treatment of Rapamycin Induces In Vitro Suppression Assay
Long-Term Acceptance and Generation of CD8 + Suppressor T Cells Spleen cells from both DBA/2 and C3H/He mice were depleted of T cells with anti-CD4/CD8-coated CD4 KO mice were transplanted with DBA/2 skin beads, treated with mitomycin C at 50 µg/ml for 30 min, allografts and were treated with or without RPM as deand used as stimulators (8 × 10 4 ) in U-bottom 96-well scribed elsewhere (26) . Long-term skin allograft surplates. CD8 + T cells from both naive and RPM-treated vival (>100 days) was achieved in all RPM-treated CD4 LTA CD4 KO recipient mice were purified and used as KO mice (n = 6), whereas rapid rejection (MST = 13 responders in mixed lymphocyte reaction (MLR). Varydays) was noted in untreated controls (n = 6, p = 0.004) ing numbers of CD8 + T cells (0, 1 × 10 5 , and 2 × 10 5 ) ( Fig. 1a ). were added to the MLR culture for 4 days. Cells were
To determine whether LTA skin grafts from RPMpulsed with [ 3 H]methylthymidine (0.5 µCi/well) in triptreated recipients were protected by CD8 + suppressor T licate for the last 12 h of culture before harvesting and cells, we did the following experiment. We challenged incorporated radioactivity was counted. Data are repre-RPM-treated hosts (n = 6) with a second DBA/2 skin sentative of three separate experiments.
graft at 100 days posttransplantation of the first graft, long after the cessation of RPM treatment. Both the first Histopathology and Immunohistochemistry and the second DBA/2 grafts were rejected, but the first Skin grafts from LTA RPM-treated CD4 KO mice grafts were rejected slower than the newly transplanted 100 days posttransplantation and tail skins from naive second grafts (p = 0.05) ( Fig. 1b ), suggesting that the DBA/2 mice were removed, snap frozen, and stored at first graft might be protected by infiltrated suppressor-−80°C. The snap frozen tissues were cut into 5-µm sectype T cells. tions, mounted on Super Frost Plus glass slides, fixed in CD8 + Suppressor T Cells Exhibit Donor-Specific formalin for 5 min, and stained in H&E for histological Hyporesponsiveness and Exert Strain-Specific Graft evaluation. Alternatively, the tissue sections were fixed Protection Upon Transfer in ice-cold acetone, rinsed in PBS, blocked with 7% horse serum for 30 min, and stained with 1 µg/ml anti-We assessed the alloantigen specificity of the CD8 + suppressor T cells in MLR in vitro. CD8 + T cells from CD4 and anti-CD8 primary mAb overnight at 4°C . The tissue sections were then blocked with 1% hydrogen naive CD4 KO mice or from LTA RPM-treated hosts were stimulated with mitomycin C-treated splenocytes peroxide and incubated with 2 µg/ml biotinylated rabbit anti-rat secondary antibody for 60 min at room tempera-from donor DBA/2 (H-2 d ) or third-party C3H/He (H-2 k ) mice. Compared to CD8 + T cells of naive CD4 KO ture. Tissue sections were then treated with avidin-biotin complex-HRP for 30 min and the signal was visualized mice, CD8 + T cells isolated from lymph nodes and spleen of LTA mice were hyporesponsive to DBA/2 do-with 3,3-diaminobenzidine.
nor strain stimulator cells (p = 0.04), but responded well Statistical Analyses to the third-party C3H/He stimulator cells ( Fig. 2a ).
Next, we tested the strain-specific graft protection by Statistical analysis was performed using GraphPad Prism 5 software. Graft survival times were analyzed by these CD8 + T cells in vivo. We transferred a mixture of CD8 + suppressor T cells from LTA mice plus CD8 + ef-Kaplan-Meier survival analysis and the statistical difference were measured using the log rank test. In the MLR, fector T cells from naive CD4 KO mice at 4:1 ratio into Rag-1−/− mice. As a control, Rag-1−/− mice were trans-comparison of the counts per minute (cpm) between the outcome of the three compared types of CD8 + T cells ferred with CD8 + effector T cells alone. Twenty-four C57BL/6 CD4 knock out (KO) mice were transplanted with DBA/2 tail skin allografts, and were either left untreated or treated with RPM as described in Materials and Methods. RPM induced universal acceptance of the grafts for >100 days, whereas untreated grafts were promptly rejected with mean survival time (MST) at 13 days. (b). After 100 days of acceptance, mice bearing the surviving grafts were either unchallenged, or challenged with the fresh second DBA/2 skin grafts. Rechallenging induced graft rejection, yet the original grafts were rejected slower than the fresh grafts.
hours later, both groups were transplanted with DBA/2 ent from that of CD8 + T effector cells from naive mice (p = 0.69) ( Fig. 2c , and data not shown). skin grafts. Transfer of 0.8 × 10 6 CD8 + suppressor T cells powerfully suppressed the ability of 0.2 × 10 6 CD8 + Functionally Active Immunoregulatory CD8 + T Cells effector T cells in rejecting the DBA/2 skin (p = 0.005)
Reside in Donor Skin Allografts and Facilitate (Fig. 2b) . Then, we transferred 2 × 10 5 CD8 + T cells LTA in RPM-Treated CD4 KO Mice from naive mice or from LTA RPM-treated hosts into Rag-1−/− mice (n = 6 for each group), followed by After we demonstrated in the aforementioned experiments that CD8 + T cells present in the secondary lym-transplanting DBA/2 (H-2 d , n = 6) or C3H/He (H-2 k , n = 6) skin grafts 24 h later. Compared to CD8 + effector phoid organs of LTA RPM-treated mice were suppressing donor-specific alloimmune response, we next investi-T cells from naive mice, CD8 + T cells from the LTA RPM-treated mice had a much delayed rejection tempo gated whether these CD8 + Treg cells home to the LTA DBA/2 skin allografts. For this, we performed histopa-of DBA/2 skins (p < 0.01), with about 30% of the grafts surviving long term (>100 days). In sharp contrast, CD8 + thology and immunohistochemistry analysis of skin allografts (n = 3) from RPM-treated mice after 100 days of T cells from the LTA RPM-treated mice promptly rejected the third-party C3H/He skins at a tempo no differ-acceptance. The results revealed that DBA/2 grafts from LTA RPM-treated hosts, but not the freshly isolated transplanted DBA/2 syngeneic grafts (n = 55) onto C57BL/6 Rag-1−/− mice as allografts that have not been DBA/2 tail skins, harbored CD8 + T cells (Fig. 3a, b) .
Then, we investigated if the graft-infiltrating CD8 + T treated with RPM. As another control, freshly prepared DBA/2 skin allografts were transplanted directly onto cells were functionally active in protecting the allografts from rejection. Due to their limited number, we used the Rag-1−/− hosts (n = 56). After a month, any graft-residing T cells will migrate out from the graft, repopulate following method to expand the graft-infiltrating CD8 + suppressor T cells: DBA/2 skin allografts (n = 5) har-the lymphopenic host, and can be detected in the circulation. FACS analysis showed that CD8 + T cells could not vested 100 days posttransplantation from LTA RPMtreated CD4 KO mice were retransplanted onto C57BL/ be detected in peripheral blood lymphocytes (PBL) from Rag-1−/− mice of the two control groups, whereas a sig-6 Rag-1−/− mice. As a control for any resident CD8 + T cells from the skin and for the transplantation process, nificant population (4.6% of PBL) of CD8 + T cells was present in PBL of Rag-1−/− recipients of LTA allografts we transplanted DBA/2 skin onto syngeneic DBA/2 hosts. Thirty days after syngeneic transplantation, we re-(p < 0.01) ( Fig. 3c ). To test for the protective function of graft-homing CD8 + T cells (from LTA RPM-treated and were either nontreated or treated with RPM alone, IL-10/Fc protein alone (IP 5 µg every other day for 5 mice) that expanded by homeostatic proliferation in Rag-1−/− mice, we adoptively transferred 0.2 × 10 6 days), or RPM + IL-10/Fc in combination. IL-10/Fc alone was ineffective and even impaired, not improved, CD8 + effector T cells from naive mice into Rag-1−/− hosts bearing either LTA DBA/2 allografts, DBA/2 allo-the graft survival in CD4 KO mice, regardless of RPM treatment (Fig. 5a ). IL-10/Fc also failed to improve graft grafts retransplanted 30 days after syngeneic transplantation, or freshly transplanted DBA/2 allografts. Under survival in CD8 KO mice (Fig. 5b) . Thus, IL-10 is unlikely to mediate the beneficial effect of RPM in pro-such rechallenge by CD8 + effector T cells, the survival of LTA DBA/2 skin allografts was significantly pro-moting CD8 + suppressor T-cell generation. longed as compared to that of the controls DBA/2 grafts DISCUSSION that have not been treated with RPM (p = 50.02) (Fig.  3d ). This indicates that RPM-treated MHC fully mis-Rapamycin (RPM) is widely used in the clinic to prevent transplant rejection. This drug is a potent and matched skin grafts in CD4 KO recipients are protected from rejection by graft-infiltrating and functionally ac-reasonably well-tolerated immunosuppressive agent. In collaboration with the Turka laboratory, we have pre-tive CD8 + Treg cells.
viously reported that RPM promotes the apoptotic death Molecular Profiles of RPM-Induced CD8 + Suppressor of many alloreactive T cells, thereby promoting toler-T Cells ance (26, 47) . In several other models, RPM enhances the efficacy of costimulatory blockade-based therapy to Based on previous reports (3,12,28), we studied the expression of surface markers CD25, CD28, CD44, induce graft tolerance (4, 27, 39, 40) , while calcineurin inhibitors block tolerance induction in these models CD122, as well as intracellular cytokine IFN-γ and IL-10 in CD8 + suppressor T cells. We found that about 18% (14, 26, 47) . We previously demonstrated that RPM promotes and synergizes with anti-CD154 to convert of CD8 + suppressor T cells from LTA RPM-treated mice expressed CD28, compared to 3.5% in CD8 + effector T peripheral alloreactive CD4 + Foxp3 − T cells into apoptosis-resistant Foxp3 + iTreg cells that can mediate donor-cells from control mice (p < 0.01) (Fig. 4a ). There were no significant differences of other surface markers such specific skin graft protection upon transfer (14). In a companion study using a pretransplant conditioning reg-as CD25, CD44, and CD122 between the two types of CD8 + T cells. In addition, while >10% of cells in the imen of donor-specific transfusion plus anti-CD154 mAb, the enhanced donor-directed Treg activity in the CD8 + effector T cell population expressed IFN-γ, only 2.3% of cells in the CD8 + suppressor T-cell population CD4 + CD25 + T-cell pool could be further strengthened by addition of RPM but not calcineurin inhibitors (14). expressed this cytokine (p < 0.01) (Fig. 4a ). There was no difference in IL-10 + cells between the two groups.
In this study, we probed for the presence of the CD8 + T cells with donor specific regulatory function. For clar-Next, we stimulated CD8 + T cells from LTA RPMtreated mice or from naive CD4 KO mice with plate-ity we utilized CD4 KO mice as recipients. CD4 KO mice vigorously reject skin allografts (46) . The mamma-bound anti-CD3 and soluble anti-CD28 mAb. ELISA analysis of day 5 and day 7 supernatants revealed that lian target of rapamycin (mTOR)-mediated signaling events seem absolutely essential for CD8 + T cell-medi-IFN-γ (p < 0.01), IL-2 (p < 0.05), and IL-10 (p < 0.05) were more robustly expressed by CD8 + T cells from na-ated rejection, as RPM, an mTOR inhibitor, preferentially inhibits the in vivo expansion of alloactivated ive mice, compared to those from the LTA RPM-treated CD4 KO mice (Fig. 4b ). Although CD8 + T cells from CD8 + T cells and uniformly produces LTA in CD4 KO mice (46) . Herein we have corroborated the ability of naive mice produced elevated levels of IL-5, IL-6, and TNF-α compared to those from the LTA RPM-treated short-term RPM therapy to promote LTA of allogeneic skin transplants in CD4 KO mice (Fig. 1a ). In these CD4 KO mice, the difference did not reach statistical significance.
hosts, allospecific CD8 + suppressor T cells are present and these cells can cause donor-specific hyporespon-IL-10/Fc Does Not Potentiate RPM to Induce CD8 + siveness in vitro ( Fig. 2a ) and protection of fully mis-Suppressor T Cells matched allogeneic skin grafts in vivo (Fig. 2b) . Following retransplantation of skin allografts har-Although RPM-induced CD8 + suppressor T cells did not seem to express IL-10, it is possible that RPM could vested from stable LTA RPM-treated CD4 KO mice onto Rag-1−/− mice, graft-infiltrating CD8 + suppressor induce the expression of this cytokine from antigenpresenting cells to potentiate the generation of CD8 + T cells migrated from the graft site, expanded in the new host, and protected test allografts from acute rejection suppressor T cells. To test this possibility, CD4 KO or CD8 KO mice (only bearing CD8 + or CD4 + T cells, re-after transfer of challenging CD8 + effector T cells (Fig.  3) . A similar finding concerning the CD4 + Treg has been spectively) were transplanted with DBA/2 skin grafts, reported by Graca et al. (16) in a model of peripheral model the existence of functionally protective CD8 + Treg cells that are CD8 + CD28 − (32). But, when they tolerance to minor histocompatibility antigen (Ag)-mismatched skin allografts and by our laboratory (11) in a tested it in a heart transplant model, they described novel CD8 + programmed death receptor 1 (PD1 + ) Treg model in which skin allograft tolerance is achieved via bone marrow transplantation, RPM, and costimulation cells induced by the blockade of the inducible costimulatory molecule and its ligand (ICOS-B7h) pathway blockade. Thus, in this model CD8 + Treg are present in both secondary lymphoid organs and reside in the allo- (20) . Our experiment demonstrated that the CD8 + suppressive T cells are CD28 + (Fig. 4a ). In line with new graft itself. These graft-homing CD8 + Treg cell are functionally active in protecting the grafts from rejection.
information concerning the diversity of CD4 + Tregs, there is a potential need for characterizing unique sub-Cosmi et al. (7) reported the existence of human CD8 + CD25 + thymocytes with regulatory activity but it populations based upon expression of homing molecules of CD8 + Treg cells that infiltrate certain microenviron-is not known whether such a subset exists in the human periphery. Bienvenu et al. have shown that CD8 + CD25 + ments (6). IL-10 is a well-documented immunosuppressant that T cells from MHC class II-deficient mice exert regulatory function (3). Endharti et al. have reported that inhibits macrophage-dependent antigen presentation and CD4 + T-cell proliferation in vitro (8, 9, 13) . Other studies CD8 + CD122 + T cells are regulatory and perform its regulatory function through production of IL-10 (12).
suggested that CD8 + suppressor T cells induce their suppressive effects via induction of IL-10 (19,31,33). How-Najafian et al. have reported in an autoimmune disease ever, our current data were not able to prove the as-toxic activity is inhibited by IL-10. These effects are indirect and are mediated through inhibition of the costi-sumed hypothesis that coadministration of RPM in combination with a recombinant IL-10/Fc of a long in mulatory functions of APC (17) . In contrast, IL-10 has no direct inhibitory effects on the proliferation of puri-vivo half-life may exert synergistic effect and possibly expand CD8 + suppressor T cells (Fig. 4c) . Moreover, the fied CD8 + T cells activated by anti-CD3 mAb and promotes the growth of activated CD8 + T cells in combina-RPM-induced CD8 + suppressor T cells secreted less IL-10 upon restimulation (Fig. 4b) with similar IL-10 intra-tion with low doses of IL-2 (35) . Taken together, these results indicate that IL-10 has cellular secretion compared to CD8 + effector T cells (Fig. 4a ). RPM is a potent anti-inflammatory agent (5) .
differing effects on CD8 + T cells depending on their state of activation. This result may help to explain the This would explain the reduced secretion of all the tested inflammatory cytokines by RPM-induced CD8 + paradox of both enhancing and inhibitory effects observed after IL-10 treatment in different in vivo experi-suppressor T cells in our study.
IL-10 inhibits alloantigen-specific proliferative responses mental models (17). In the system studied in this report, the use of IL-10/Fc as an adjunct to RPM resulted in and induces a long-lasting anergic state in human purified CD8 + T cells when added concomitantly with the results inferior to RPM monotherapy with respect to graft survival in CD4 KO mice with no positive effect antigen in the presence of antigen presenting cells (APC). Moreover, the generation of allospecific cyto-on CD8 KO mice. 
